Click the link below to sign up for our emails! We don’t bombard you, we send emails when they matter. Like with our NIH grant announcement, or breakthroughs in research. As a non-profit, we work for patients, and we strategically target our research to move the dial on treatments for #ME and #Longcovid.

We’re so excited about our @NIH R-01 grant that we wanted to tell you a little bit more about it! Click below to take a look at how we got it and what we can and can’t use it for! It can’t be overstated that this couldn’t have been done without our amazing researchers, collaborators, patients and donors! bit.ly/4yqWVwR #ME #Longcovid

We did it! We are so excited to announce we have received a prestigious R-01 grant from @NIH to further our research into mTOR’s role in #MECFS! This grant will deepen our findings about how mTOR activation is contributing to #PEM and help pinpoint mechanisms that are disrupted in #ME to better target treatments. Congratulations, @ggottschalkPhD @ProfAvikRoy and team! #Longcovid #POTS

Read a short summary of our findings on purine dysregulation and how rapamycin might moderate it for #ME patients. Purine is the 2nd of 3 pathways we found disrupted in our rapamycin treatment trial, as published in the Journal of Translational Medicine. #PEM #Longcovid Check it out here: bit.ly/4y1qepL

Our rapamycin studies are very promising, yet we know the findings need to be confirmed in a placebo-controlled trial. Listen to Dr. Gunnar Gottschalk explain why we studied mechanisms of rapamycin in responders, and how a random controlled trial can cut through heterogeneity in #ME. #PEM #POTS #Longcovid

The recently published findings from Phase II of our rapamycin treatment trial describe 3 pathways that are disrupted in #ME patients and are improved through treatment with Rapamycin. We summarize those findings in a series of updates, starting with mitochondrial dysfunction. Check it out bit.ly/4xhafmi #MECFS #ME #Longcovid #POTS

Interested in finding out more about our #ME and #LongCovid research and upcoming work? Sign up for email updates! simmaronresearch.com/signup #MECFS #POTS

Take a listen to the Rapamycin trial summary from Dr. Roy and how it will impact the future of clinical studies including Rapamycin.

Dr. Roy highlights the benefits of Rapamycin for ME/CFS patients. Listen now to hear how just how these benefits impact patients.

Dr. Avik Roy summarizes our first scientific aim with Phase II of the rapamycin trial. Take a listen for yourself and find out why this trial is different from past endeavours.

Does Rapamycin improve mitochondrial energy metabolism in ME/CFS patients? Listen to Dr. Avik Roy explain the importance of mitochondrial energy and the impact found in the Rapamycin trial.

3 broken pathways rapamycin starts to repair in a subset of #ME. Hear Simmaron’s Chief Science Officer introduce our recent publication. As a non-profit, we work for patients. #longcovid #PEM #POTS

Why Rapamycin? And why now? Our Journal of Translational Medicine publication starts to answer that for an #ME subset. @JTR @UWM @ProfAvikRoy @ggottschalkPhD #longcovid #PEM

Simmaron’s science is led by award winning microbiologists. Our treatment trial is run by #ME and #Longcovid clinicians. Our animal models are collaborations with the leading Milwaukee Institute for Drug Discovery @UWM. ME caregivers lead our Board. As a non-profit, we need your help. Donate! simmaronresearch.com/donate

One of the biggest challenges in #MECFS research has been patient heterogeneity. Not every patient has the same underlying biology. Our Phase II study of Rapamycin further supports the concept that biomarkers—including markers of autophagy dysfunction and altered purine metabolism—may help identify patients most likely to benefit from targeted therapies. Rather than asking: "Does this drug work for everyone?" We should be asking: "Which patients is this drug designed to help?" That is the future of clinical trials for #ME and #Longcovid. #PrecisionMedicine #POTS #PEM

Our groundbreaking science needs your support! Simmaron is a small non-profit making big findings. Keep us moving on new findings of polarized macrophages caused by mTOR activation in muscle fatigue in #ME and #Longcovid. bit.ly/Simmaron

Our decentralized #rapamycin trial allowed #SevereME patients to participate. When necessary, we reduced blood draw volumes. For questionnaires, we made every effort to help patients complete them. In a few cases, this meant conducting surveys over the phone in multiple sessions. We all need new models. #ME #MECFS #Longcovid